Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine.

Publisher: Mosby Country of Publication: United States NLM ID: 0370465 Publication Model: Print Cited Medium: Print ISSN: 0002-8703 (Print) Linking ISSN: 00028703 NLM ISO Abbreviation: Am Heart J Subsets: MEDLINE

Original Publication: St. Louis, MO : Mosby

Angioplasty, Balloon, Coronary*; Coronary Circulation/*drug effects ; Myocardial Infarction/*physiopathology ; Myocardial Infarction/*therapy ; Papaverine/*pharmacology ; Vasodilator Agents/*pharmacology; Adult ; Aged ; Coronary Angiography ; Female ; Heart/physiology ; Humans ; Male ; Middle Aged ; Myocardial Infarction/diagnostic imaging ; Regional Blood Flow

The no-reflow phenomenon is observed as reduction of coronary blood flow on the angiograms (angiographic no-reflow) after immediate percutaneous transluminal coronary angioplasty (PTCA) in patients with acute myocardial infarction (AMI). To assess whether a potent coronary microvascular dilator--papaverine--could attenuate the no-reflow phenomenon, nine patients with AMI who were found to have angiographic no-reflow after PTCA were studied. Angiographic no-reflow was defined as the Thrombolysis in Myocardial Infarction flow grade 1 or 2 without any mechanical obstructions in the epicardial artery. A bolus dose of 10 mg of intracoronary papaverine was administered, and the flow grade was again evaluated. Intracoronary papaverine caused a significant improvement of the flow grade (p= 0.0152). The number of cineframes that were required for the contrast medium to pass two selected landmarks on the angiograms also significantly decreased (41 +/- 17 frames to 18 +/- 8 frames, p= 0.0039). Thus intracoronary papaverine attenuated angiographic no-reflow that occurred after PTCA for AMI.

0 (Vasodilator Agents)
DAA13NKG2Q (Papaverine)

Date Created: 19961101 Date Completed: 19961223 Latest Revision: 20190626

20231215

10.1016/s0002-8703(96)90005-8

8892767